Clinical trials
Phase 1 Cholangiocarcinoma trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
84 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 9 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 8 |
| 2021 | 6 |
| 2022 | 8 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 4 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 31 |
| Terminated | 22 |
| Recruiting | 12 |
| Active, not recruiting | 11 |
| Withdrawn | 4 |
| Not yet recruiting | 2 |
| Suspended | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 5 |
| Eli Lilly and Company | 4 |
| Mayo Clinic | 4 |
| Celldex Therapeutics | 3 |
| Jonsson Comprehensive Cancer Center | 3 |
| AbbVie | 2 |
| City of Hope Medical Center | 2 |
| MacroGenics | 2 |
| NGM Biopharmaceuticals, Inc | 2 |
| National Cancer Institute (NCI) | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholangiocarcinoma | 84 |
| Colorectal Neoplasms | 29 |
| Carcinoma, Non-Small-Cell Lung | 22 |
| Ovarian Neoplasms | 22 |
| Pancreatic Neoplasms | 21 |
| Stomach Neoplasms | 19 |
| Carcinoma, Hepatocellular | 14 |
| Esophageal Neoplasms | 14 |
| Melanoma | 14 |
| Breast Neoplasms | 12 |
Trials
Showing 1 to 25 of 84. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.